Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

تحليل معلومات السوق

مدعوم بالذكاء الاصطناعي 60% FREE-ANALYSIS-RULE-BASED-ANALYSIS
لماذا هذا مهم

Analysis of stock market developments showing bearish sentiment.

المشاعر
Bearish
ثقة الذكاء الاصطناعي
60%
الأفق الزمني
قصير الأجل
Affected Symbols

سياق المقال

ملاحظة: هذا مقتطف موجز للسياق. انقر أدناه لقراءة المقال الكامل على المصدر الأصلي.

On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update. (Source: Bloomberg)

متابعة القراءة
المقال الكامل على Bloomberg
قراءة المقال الكامل
AI Breakdown

ملخص

Analysis of stock market developments showing bearish sentiment.

الأفق الزمني

قصير الأجل

المقال الأصلي منشور بواسطة Bloomberg في مايو 18, 2026.
التحليل والرؤى المقدمة من AnalystMarkets AI.